On April 15, 2026 Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, reported that there will be two customer posters presented at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) annual meeting on April 17-22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster 2421; April 20, 2026
Primary Author: Nigel O’Neil, PhD
Poster Title: Combining deep mutational scanning and next-generation protein sequencing to harness dominant protein variants to develop DNA repair inhibitors

In the first poster, the researchers describe a complementary genetic (high throughput screens) and proteomic (benchtop protein sequencing) approach to find and model the behavior of therapeutics targeting DNA repair enzymes.

Poster 7650; April 22, 2026
Primary Author: Gloria Sheynkman, PhD
Poster Title: High-resolution detection of post-translational modifications using single-molecule protein sequencing

In the second poster, the researchers demonstrated the ability to resolve and quantify multiple PTMs using Quantum-Si’s single-molecule protein sequencing technology. The authors suggested that the technology could be used to add proteoform characterization to biomarker studies, providing additional resolution not readily available in broad biomarker screening panels. The authors further concluded that they expect this technology could democratize advanced protein characterization, making the high-resolution detection of PTMs available to a broader scientific community.

"We are excited to see new customer data being presented at key industry conferences like AACR (Free AACR Whitepaper), that continue to demonstrate the power of our proprietary single-molecule protein sequencing technology," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "We invested significant effort during 2025 to build a pipeline of studies that would demonstrate the power of our technology, and we are very pleased to have a steady flow of customer pre-prints, publications and posters being released this year as we work to expand awareness and build momentum towards the launch of Proteus."

(Press release, Quantum SI, APR 15, 2026, View Source [SID1234664420])

On April 15, 2026 Zephyr AI, Inc. ("Zephyr AI"), a leader in precision medicine harnessing artificial intelligence to accelerate drug development, reported its schedule of research presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting in San Diego, California, April 17-22, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s posters will be presented by senior researchers and highlight novel work Zephyr AI is advancing with its biopharmaceutical and life science partners. The presentations feature multimodal AI approaches for predicting response to targeted therapies in patients with cancer, as well as checkpoint inhibitor response in patients receiving combination treatment. Across these investigations, Zephyr’s AI models operate on clinically available inputs—including liquid biopsy DNA, tissue-based molecular data, and whole-slide images—to generate drug response predictions and biological insights into tumor-intrinsic and tumor microenvironment features associated with treatment response.

"We are thrilled to showcase Zephyr AI’s work at this year’s AACR (Free AACR Whitepaper) meeting," said Zephyr AI CEO Allen Chao, PhD. "The utilization of AI with multimodal data and clinically available inputs is transforming research and accelerating discovery. This is a wonderful opportunity to share how our novel approach is helping drive important advances in cancer treatment."

Official schedule of Zephyr AI presentations at AACR (Free AACR Whitepaper):

Real world prediction and biological characterization of sotorasib sensitivity using multimodal AI and liquid biopsy genomic inputs (Presentation 5235)

Session Title: Biomarkers Predictive of Therapeutic Benefit 5
Presenter: Emily Vucic, VP Science
Session Date & Time: April 21, 9:00AM – 12:00PM
Location: Poster Section 42
Poster Board Number: 1

Multimodal AI predicts immune checkpoint inhibitor response from clinically available inputs and whole-slide images with explainable tumor biology and combination therapy insights (Presentation 1014)

Session Title: Biomarkers Predictive of Therapeutic Benefit 1
Presenter: Maayan Baron, Assoc Dir of Computational Biology
Session Date & Time: April 19, 2026 2:00PM – 5:00PM
Location: Poster Section 40
Poster Board Number: 8

Leadership from Zephyr AI will be attending AACR (Free AACR Whitepaper). Please contact [email protected] to request a meeting.

(Press release, Zephyr AI, APR 15, 2026, View Source [SID1234664419])

On April 15, 2026 Agilent Technologies Inc. (NYSE: A) reported it will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode microplate readers. Cytation 9 is designed to support advanced live‑cell and endpoint assays by combining automated microscopy with conventional microplate reading in a single system, supporting a range of cell‑based research applications.

In addition, Agilent will provide an early preview of the upcoming AI‑enabled software enhancement for the xCELLigence RTCA eSight, designed to bring the same straightforward, objective data analysis long valued in impedance measurements to label‑free live‑cell imaging, while supporting more consistent, reproducible results.

AACR attendees are invited to join Agilent at the Exhibitor Spotlight Theater for a session titled "Direct Targeted Methylation Sequencing (dTMS) with SureSelect: Targeted Long‑Read Sequencing for Native Variant and Methylation Profiling in Oncology." The session will be presented by Andrew Jenkins, biotechnology research associate at Wasatch Biolabs, and will examine the use of targeted long‑read sequencing approaches in oncology research.

Agilent will also highlight its collaboration with Oxford Nanopore Technologies, demonstrating the compatibility of Agilent SureSelect target enrichment chemistry with ONT’s long-read sequencing platforms. By integrating SureSelect libraries into ONT sequencing workflows, researchers can pair hybrid-capture target enrichment with real-time, long-read sequencing to support applications such as target genomics, structural variant analysis, and methylation profiling.

Immediately preceding AACR (Free AACR Whitepaper) 2026, Agilent’s xCELLigence User Group Meeting will bring together the real-time cell analysis community to share best practices, applications, and real-world insights from functional cell-based research.

Agilent is continuing its collaboration with the AACR (Free AACR Whitepaper) Foundation following a virtual 5K fundraiser held in October 2025 that raised $15,000 and funded 14 Scholars-in-Training awards. Agilent representatives will meet scholars supported through this initiative at the AACR (Free AACR Whitepaper) Scholar‑in‑Training Award Reception and will promote the 5k fundraiser at the Agilent booth as part of its ongoing commitment to supporting early-career cancer researchers.

"At Agilent, our mission is to support advances in cancer research by providing integrated technologies and collaborative solutions," said Rita Shaknovich, chief medical officer at Agilent Technologies. "By delivering trusted answers, we aim to help researchers and clinicians make more informed decisions across the cancer research and care continuum."

Agilent will exhibit at booth No. 4527 and host additional scientific and networking events throughout the meeting.

(Press release, Agilent, APR 15, 2026, View Source [SID1234664418])

On April 15, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developing novel diagnostic solutions for deep molecular characterization of hematologic malignancies with a focus on circulating tumor cells, reported the commercial expansion of a co-branded whole-genome sequencing (WGS) assay, currently known as GenoPredicta, intended for the comprehensive genomic characterization of hematologic malignancies and measurable residual disease (MRD) monitoring.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GenoPredicta is an ultrasensitive assay that extracts deep genetic insights from peripheral blood or bone marrow. By integrating flow cytometry for precise tumor cell detection and enumeration with WGS, the assay delivers a comprehensive analysis of a cancer genome. It identifies genetic alterations (SNVs/indels, CNVs, SVs)—from as few as 50 tumor cells, corresponding to a sensitivity as low as one in a million cells—to aid in diagnosis, risk classification, and the identification of therapy resistance mechanisms. This sensitivity expands testing eligibility to cases with low tumor burden.

The assay is currently available to Tempus’ Life Sciences partners to support exploratory research and clinical development programs. The assay has been clinically validated in Multiple Myeloma and other plasma cell dyscrasias and is available for research use only across other indications. The technology powering the assay stems from the foundational work of Predicta scientific co-founder Dr. Irene Ghobrial, whose research redefined early detection and intervention in blood cancers.

"By joining forces with Tempus, we are delivering unprecedented sensitivity and clarity to researchers – enabling the potential for earlier detection, smarter treatment decisions, and a deeper understanding of disease biology from a single assay," said Brian McKernan, CEO of Predicta Biosciences. "This partnership with Tempus will help accelerate market adoption and the utility of our tests in order to optimize clinical trials."

"GenoPredicta offers a novel, unified solution for our life science partners and a comprehensive replacement for traditional, siloed testing," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "By consolidating flow cytometry, cytogenetics, and WGS into one ultrasensitive workflow, we can identify high-risk biomarkers and track clonal evolution from as few as 50 tumor cells. Crucially, because the assay delivers 100% concordance between peripheral blood and bone marrow, it can provide these deep insights while sparing patients from biopsies."

(Press release, Tempus, APR 15, 2026, View Source [SID1234664417])

On April 15, 2026 Quanterix Corporation (Nasdaq: QTRX) reported plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026. Built on the integration of Akoya Biosciences’ spatial biology platform and Quanterix’s decades of ultra-sensitive, quantitative immunoassay development from the SIMOA technology, the Content Innovation Engine is organized around the hallmarks of cancer framework, giving researchers a systematic, biology-first approach to revealing more from every tissue section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

It is supported by the end-to-end capabilities spatial biology needs to advance beyond discovery: world-class spatial instrumentation, and the assay design and reagent formulation expertise, quality systems, and manufacturing scale to support measurements that meet the requirements of translational and clinical applications.

"Spatial biology has fundamentally changed how we see cancer," said Everett Cunningham, President and CEO of Quanterix. "Akoya built a platform that gave researchers an entirely new way to study it. What Quanterix brings is the assay expertise, quality systems, and scale to carry that science further, into translational settings, into the clinic, into decisions that affect patients. The Content Innovation Engine is the first expression of what that combination makes possible."

IO60 Named Edison Award Finalist; Spike-In Module Deepens Immunotherapy Biology

The PhenoCode Discovery IO60 panel has been named a Finalist in the Edison Awards. At AACR (Free AACR Whitepaper), Quanterix will introduce a new IO60 Spike-In Module extending biological coverage into two high-priority areas: checkpoint therapy markers spanning PD-1/PD-L1, CTLA-4, and next-generation blockade; and tertiary lymphoid structure (TLS) markers, an emerging correlate of durable immunotherapy response.

ADC + IO: Combination Biology in a Single Tissue Section

New high-plex ADC content compatible with IO60 and PhenoCode Discovery panels on PhenoCycler-Fusion will enable co-measurement of ADC target expression and tumor immune contexture in a single tissue section. This addresses growing demand for combination biology readouts at the ADC-immunotherapy interface.

PhenoCode Molecular Barcoding Kit, Debuting at AACR (Free AACR Whitepaper), Early Access May 2026

Quanterix will introduce the PhenoCode Molecular Barcoding Kit at AACR (Free AACR Whitepaper), built on a new PhenoCode 2.0 chemistry. The kit enables researchers to barcode virtually any antibody of their choice with exceptional reliability and yield. Existing panels can be expanded into immuno-oncology, neuroscience, and beyond without adding complexity to the workflow. Early access begins May 2026. Attend the live in-booth presentation at Booth 2028 on April 20, 11:30 AM to 12:00 PM to learn more.

PhenoImager HT: Two New ADC Lung Cancer Panels, Available Now via Accelerator

The Accelerator Service Lab will present two new ADC lung cancer panels for PhenoImager HT at AACR (Free AACR Whitepaper). Building on the ADC breast cancer panel debut at AACR (Free AACR Whitepaper) 2025, both panels are available today as a fully managed service. Attend the live in-booth presentation at Booth 2028 on April 21, 11:30 AM to 11:45 AM for details.

Quanterix’s growing spatial biology community will also be represented at AACR (Free AACR Whitepaper) 2026, with 25+ posters from customers and collaborators presenting data generated on PhenoCycler-Fusion and PhenoImager HT across a range of cancer indications.

For more information visit: View Source

(Press release, Quanterix, APR 15, 2026, View Source [SID1234664416])